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Summary The effects of the combination of cisplatin and other cytotoxic agents were studied in vitro. When
A549 lung cancer cells were treated simultaneously with cisplatin and other cytotoxic agents, cisplatin
additively increased the cytotoxic effects of etoposide, mitomycinC, adriamycin, 5-fluorouracil and 1-fl-D-
arabinofuranosylcytosine, but antagonised those of vincristine, vindesine, vinblastine and podophyllotoxin.
The antagonism between cisplatin and vincristine was also observed with HT29 colon cancer cells, NC65
renal carcinoma cells and A431 epidermoid carcinoma cells.when these cells were simultaneously exposed to
both agents. When A549 cells were exposed to cisplatin and vincristine sequentially, the antagonism between
them was evident when cells were pretreated with cisplatin' but not when treated in the opposite sequence.
Therefore, when combination chemotherapy including cisplatin and vinca alkaloids is given, possible
antagonism between them should be considered, especially in determining the schedule of drug administration.
Combinations of cisplatin and one of the vinca alkaloids
have been shown to have marked activity against a wide
variety of clinically encountered neoplasms (Einhorn &
Donohue, 1977; Spaulding et al., 1980; Gralla et al., 1981;
Kelsen et al., 1982). However, little is known about the
pharmacological interactions between cisplatin and vinca
alkaloids. In this study, we demonstrate that cisplatin
antagonises the cytotoxic effects of vinca alkaloids against
human tumour cells in vitro and that the antagonism
between them is dependent on the schedule of drug
administration. These results demonstrate the importance of
properly scheduling drug administration when employing a
combination of cisplatin and vinca alkaloids.
Materials and methods
Cells and reagents
A549 lung cancer cells were obtained from Dr Michael B.
Sporn, HT29 colon cancer cells from Dr Nobuhiko
Tanigawa and A431 epidermoid carcinoma cells from Japan
Cancer Research Resource Bank. These three cell lines and
NC65 renal carcinoma cells (Hoehn & Schroeder, 1978) were
grown in a humidified 5% CO2 atmosphere at 37°C using
Dulbecco's modification of Eagle's medium supplemented
with 10% fetal calf serum. The same culture conditions and
culture medium were used throughout this study. Drug
solutions were made freshly for each experiment.
Monolayer assays
Simultaneous exposure. In this study, cells were treated with
cisplatin and one of other cytotoxic agents simultaneously
and continuously unless otherwise indicated. Some 5 x 104
cells were plated in the wells of 24-well culture plates and
cultured overnight. Then the combinations of serial two-fold
dilutions of cytotoxic agents were added in chequer-board
fashion (Sande & Mandell, 1985). After cells were cultured
for 3 days in the presence of drugs, cellular survival was
determined as previously described (Sugarman et al., 1985).
In brief, at the termination of cultures, cells were fixed and
stained with 0.5% crystal violet/20% methanol and the
amounts of the dye that had stained the cells were measured
by absorbance at 540 nm after elution into 0.1 M sodium
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citrate/50% ethanol. The percentage survival was defined as
OD540(drugs)/OD540(control) X 100 (%)-
Sequential exposure. Some 5 x 104 cells were plated in the
wells of 24-well culture plates and cultured overnight. Then
one of either cisplatin or vincristine was added and cells were
incubated for 6 hours. Cells were washed with phosphate-
buffered saline (PBS) three times, and were again incubated
for 6 hours with the other agent. Then cells were washed
again with PBS three times and cultured for 3 days in the
absence of drugs. Cellular survival was determined as
described above.
Soft agar assays
Some 3 x 103 cells in 1 ml 0.3% agar were plated over
underlayers of 1 ml 0.5% agar containing specified amounts
of combined cytotoxic agents prepared in 35 mm Petri
dishes. After cells were cultured for 10 days, they were
stained with 0.1% 2-(p-iodophenyl)-3-(p-nitrophenyl)-5-
phenyl tetrazolium chloride (INT) (Alley et al., 1982). Cell
clusters larger than 60jM were counted as colonies using an
inverted microscope. The percentage survival was defined as
colonies(drugs)/colonies(control) X 100 (%).
Results
The cytotoxic effects of cisplatin on A549 cells were assessed
with the monolayer assay described above in five separate
experiments in order to evaluate the validity of the assay
system (Figure 1). The intra-assay variations were less than
10% in each of five experiments and interassay variations
among those five experiments were less than 20%.
The cytotoxic effects of adriamycin, 5-fluorouracil (5FU),
etoposide, 1-p-D-arabinofuranosylcytosine (Ara C) and
mitomycin C (MMC) against A549 lung cancer cells in
monolayer cultures were enhanced by combinations with
cisplatin, as shown in Figure 2. The dose-response curves of
these agents shifted downwards parallel to the increasing
doses of cisplatin. As illustrated by the isobologram for the
75% inhibitory dose (ID75) of the combination of cisplatin
and MMC demonstrated in Figure 2, isobologram analysis
(Sande & Mandell, 1985) based on these dose-response
curves showed additivism between cisplatin and these five
cytotoxic agents.
In contrast, the cytotoxic effects of vincristine, vindesine,
vinblastine and podophyllotoxin against A549 cells were
antagonised by cisplatin (Figures 3 and 4). The slopes of the
dose-response curves of three vincas and podophyllotoxin
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The antagonistic effects of cisplatin on the cytotoxicity of
vincristine on A549 cells were also observed with a soft agar
colony assay (Figure 5). Less colony inhibition was achieved
by the combination of cisplatin and vincristine than by
vincristine alone when the concentrations of vincristine
exceeded 125 ngml-1. The antagonism between cisplatin and
vincristine was not specific for A549 cells. Cisplatin also
decreased the cytotoxic effects of vincristine on HT29 colon
cancer cells, NC65 renal carcinoma cells and A431
epidermoid carcinoma cells (Figure 6).
The interaction between cisplatin and vincristine was
dependent on the sequence of their administration (Figure
7). When A549 cells were exposed for 6 hours to either of
these agents sequentially, the antagonism between them was
observed only when cells were pretreated with cisplatin.
Although the dose-response curves of vincristine shifted
downwards in parallel with increasing doses of cisplatin
when cells were first treated with vincristine, they became
flat, as in the case with continuous and simultaneous
exposure, when cells were exposed to these agents in the
opposite sequence.
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Figure 1 Cytotoxic effects of cisplatin on the monolayer growth
of A549 cells (a) Dose-response curves obtained from five
separate experiments. After cells had been cultured overnight and
allowed to adhere to culture plates, they were cultured with the
indicated doses of cisplatin for 3 days. Percentage survival was
determined as described in Materials and methods. Each assay
was run in quadruplicate (bars represent standard deviations). (b)
Interassay variations; means and standard deviations of the five
different experiments shown in (a).
became flatter with increasing doses of cisplatin.
Consequently, the dose-response curves of these agents
obtained in the presence of various doses of cisplatin crossed
over with the curves obtained in the absence of cisplatin; i.e.
beyond the cross-over points, higher cytotoxic effects were
achieved by vinca alkaloids and podophyllotoxin alone than
by combinations with cisplatin (Figure 3). It should be noted
that isobols could not be specified for these combinations
because of the flattening of the dose-response curves.
In this study we demonstrate that the cytotoxic effects of
vinca alkaloids as well as those of podophyllotoxin against
certain human tumour cells are antagonised by cisplatin,
while combinations of cisplatin with other agents, such as
adriamycin, 5-FU, etoposide, Ara C and MMC, are additive.
We also demonstrate that the antagonism between cisplatin
and vincristine is dependent on the schedule of their
administration.
The mechanism of the antagonism between cisplatin and
vincas or podophyllotoxin is unknown. Vinca alkaloids and
podophyllotoxin are both classified as 'spindle poisons'
because they bind to tubulin, a component protein of
microtubules, thereby preventing polymerisation of micro-
tubules and formation of mitotic spindles (Wilson et al.,
1974; Himes et al., 1976). Although they cause mitotic arrest
of cells, vincristine and vindesine have been shown to exert
maximum cytotoxicity on cells in S-phase (Madoc-Jones &
Mauro, 1974). One possible explanation for the antagonism
between cisplatin and these tubulin-binders is that cisplatin
may block cells to traverse S-phase, when cells are most
sensitive to them. However, as the cytotoxic effects of other
S-phase specific agents, such as 5-FU and Ara C, were
additive to those of cisplatin with the same assay system
(Figure 2), phase-specificity of vincas and podophyllotoxin
does not fully explain the antagonism with cisplatin.
Whether or not the alterations of cell cycle kinetics could
play a role in this antagonism awaits further definitive
studies, including the flow cytometric analysis of the cell
cycle of cells under treatment with combinations of cisplatin
and various phase-specific agents.
Another possible explanation for the antagonistic inter-
action between them is that cisplatin interferes with the
major action site of vinca alkaloids and podophyllotoxin, i.e.
inhibition of polymerisation of microtubules. While the
cytotoxic effect of cisplatin is thought to be exerted by its
aqueous form through the formation of cross-linking of
DNA chains (Rosenberg, 1985), hydrolysed cisplatin has also
been shown to inhibit microtubule polymerisation, although
it is not clear whether hydrolysed cisplatin reacts with
tubulin or microtubule-associated proteins (Peyrot et al.,
1983). In addition, peripheral neuropathy, a side effect
common to vincas, has also been reported for cisplatin
(Reinstein et al., 1980; Cowan et al., 1980). If cisplatin
antagonises the effects of vincas by blocking their major
action site, prior exposure of cells to cisplatin could result in
more marked antagonism than when cisplatin follows the
vincas; and this was the case with the interaction between
cisplatin and vincristine on A549 cells (Figure 7). Moreover,
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Figure 2 Cytotoxic effects of the combination of cisplatin and other cytotoxic agents on the monolayer growth of A549 cells. (a)
Dose-response curves of five cytotoxic agents obtained in the absence and presence of cisplatin. Concentrations of cisplatin were 0
(0), 1.25 (0), 2.5 (A) and 5 (El),gm-1. Each assay was run in quadruplicate and percentage survival was determined as
described in Materials and methods (bars represent standard deviations). Experiments were repeated twice with similar results. (b)
Isobologram for the combination of cisplatin and MMC for 75% inhibitory dose. Isobols obtained from the dose-response curves
shown in (a) (0). Isobols obtained similarly with a different experiment (x).
Vincristine (ng ml-')
0 128 256 512
I
'°°r
co
D 10
Vindesine (ng ml-')
0 32 64 128
e . .-I
Vinblastine (ng ml-')
0 64 128 256
Podophyllotoxin (ng ml-')
0 8 16 32
9 . .a-
Figure 3 Effects of vinca alkaloids and podophyllotoxin on the monolayer growth of A549 cells in the absence and presence of
cisplatin. Concentrations of cisplatin were 0 (0), 0.63 (0), 1.25 (A), 2.5 (Ol) and 5 (x)pgml-'. Each assay was run in
quadruplicate and percentage survival was determined as described in Materials and methods (bars represent standard deviations).
Experiments were repeated three times with similar results.
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Figure 4 Crystal-violet staining of A549 cells treated with
vinblastine in the presence and absence of 2.5jugml-1 cisplatin.
Cells were cultured and stained as described in Materials and
methods.
it should be noted that while the cytotoxic effects of
podophyllotoxin on A549 cells were antagonised by cisplatin,
those of etoposide, a derivative of podophyllotoxin, were
shown to be additive to cisplatin (Figures 2 and 3). As
etoposide neither binds to tubulin nor prevents microtubule
polymerisation (Krishan et al., 1975; Loike & Horwitz,
1976), only tubulin-binding agents may be specifically
antagonised by cisplatin.
Contrary to the results of our in vitro experiments,
combinations of cisplatin and vincas have been shown to
produce significantly higher response rates against a wide
variety of clinically encountered neoplasms than when each
agent is used alone (Einhorn & Donohue, 1977; Spaulding et
al., 1980; Gralla et al., 1981; Kelsen et al., 1982). The
dissociation between the antagonism observed with in vitro
experiments and the therapeutic synergism obtained in the
clinical setting could be explained by the schedule-
dependence of this interaction. As cisplatin is administered at
3- or 4-week intervals and vincas at weekly intervals in most
chemotherapeutic regimens, it may be that the antagonism
between them is masked by this schedule. Nevertheless, as
far as pharmacological interactions are concerned, cisplatin
antagonises the cytotoxic effects of tubulin-binding vinca
alkaloids, at least under the experimental conditions
described here. Moreover, it is possible that better
therapeutic responses could be achieved if drug schedules are
constructed to avoid the possible antagonism between them.
It may be beneficial to avoid administration of cisplatin
immediately before that of vinca alkaloids or at least to
avoid simultaneous administration of these agents.
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Figure 5 Effects of vincristine on the colony formation of A549
cells in the absence and presence of cisplatin. (a) Dose-response
curves of vincristine in the presence of 0 (0), 0.16 (O), 0.31 (A),
0.63 (El) and 1.25 (x )pgml- cisplatin. Control plates gave
1,438 (±102) colonies per plate (plating efficiency was 47.9%).
Assays were run in duplicate and percentage survival was
determined as described in Materials and methods (bars represent
standard deviations). Experiments were repeated twice with simi-
lar results. (b) Colony formation of A549 cells (x 20, stained
with INT) in the presence of (I) 250ngml-I vincristine alone
and (II) 250ngml-I vincristine and 1.25 ggml-I cisplatin.
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Figure 6 Effects of vincristine on the monolayer growth of HT29, NC65 and A431 cells in the absence and presence ofcisplatin.
Concentrations of cisplatin were 0 (0), 0.63 (0), 1.25 (A\), 2.5 (C1) and 5 (x) ygmIm . Each assay was run in quadruplicate and
percentage survival was determined as described in Materials and methods (bars represent standard deviations). Experiments were
repeated twice with similar results.
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Figure 7 Schedule dependence of the interaction between cis-
platin and vincristine. A549 cells were exposed (a) first to
cisplatin for 6 h and then to vincristine for another 6 h or (b) in
the opposite sequence. Concentrations of cisplatin were 0 (0),
2.5 (0), 5 (A) and 10 (_l)ygml1. Cells were grown in
monolayer cultures and assays were run in triplicate. Percentage
survival was determined as described in Materials and methods
(bars represent standard deviations). Experiments were repeated
twice with similar results.
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